Ulcerative colitis
Conditions
Interventions
One group is to receive two-week combination therapy consisting of amoxicillin (Sawacillin) 500 mg t.i.d, tetracycline (Acromycin) 500 mg t.i.d, and metronidazole (Flagyl) 250 mg t.i.d. with an inhibi
Sponsors
Division of General Medicine, Department of Internal Medicine, Nihon University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Eligibility criteria for study entry are mild-to-severe, chronically relapsing UC and a Lichtiger Clinical Activity Index of at least 6 or a Mayo score of more than 5. 2) Patients able to visit the hospital during follow up 3) Cases whose doctors decided that they would be able to provide adequate answers during an interview 4) Patients providing informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with diarrhea and fever, unable take the medications and those with toxic megacolon 2) Patients allergic to penicillin 3) Patients allergic to SASP and 5-ASA 4) Pregnant patients. Cases with complications of other severe diseases, such as renal and hepatic disorders. 5) Patients with mental disorders, and so on, considered by their doctors to be unsuitable candidates for clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission and clinical response | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment failure rate | — |
Countries
Japan
Contacts
Public ContactKimitoshi Kato
Nihon University School of Medicine, Itabshi Hospital Division of General Medicine, Dept. of Internal Medicine
Outcome results
None listed